Journal
NATURE REVIEWS MICROBIOLOGY
Volume 6, Issue 1, Pages 17-27Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrmicro1818
Keywords
-
Categories
Funding
- NIAID NIH HHS [R01AI048689, R01 AI029549, R01AI029549, R01 AI048689] Funding Source: Medline
- NIDDK NIH HHS [R01DK51406, P50 DK064540, P50-ORWH/DK64540, R01 DK051406] Funding Source: Medline
- NIGMS NIH HHS [R01 GM068460, R01GM068460, R01 GM068460-03] Funding Source: Medline
- PHS HHS [T32A107172] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549, R01AI048689] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406, P50DK064540] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068460] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The emergence and increasing prevalence of bacterial strains that are resistant to available antibiotics demand the discovery of new therapeutic approaches. Targeting bacterial virulence is an alternative approach to antimicrobial therapy that offers promising opportunities to inhibit pathogenesis and its consequences without placing immediate life-or-death pressure on the target bacterium. Certain virulence factors have been shown to be potential targets for drug design and therapeutic intervention, whereas new insights are crucial for exploiting others. Targeting virulence represents a new paradigm to empower the clinician to prevent and treat infectious diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
